Eli Lilly and Company

Margaret Mary Faul

Leonard Larry Winneroski, Jr

Michael R Jirousek

John H McDonald, Iii

Russell Dean Stucky

Samuel James Dominianni

David Andrew Neel

Gary Lowell Engel

Lori Ann Richardson

Nagy Alphonse Farid

John M Schaus

Thomas Daniel Aicher

David Edward Tupper

Vincent Patrick Rocco

Joseph H Krushinski, Jr

Dennis C Thompson

Zhaogen Chen

Yvan Le Huerou

Julie Kay Bush

Ying Chen

Susan Marie Reutzel-Edens

Marta Maria Pineiro-Nunez

Kevin Michael Ruley

Leonard L Winneroski Ii

Christine Ann Krumrich

The present invention relates to crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-yl-methyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride salt, a pharmaceutical formulation containing said salt and to methods for treating cancer and for inhibiting tumor growth using said salt.

Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride

Described herein are antipyschotic compounds of formula (I) wherein,

Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders

This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia.

Hypoglycemic and hypolipidemic compounds

The present invention provides for the reaction of optionally substituted indole-3-acetamides with optionally substituted methyl indole-3-glyoxyl reagent to prepare potent PKC inhibitors. The reaction is very efficient and robust macrocyclization methodology.

Synthesis of bisindolylmalimides

This invention provides novel bis-indolylmaleimide macrocycle derivatives of the formula: ##STR1## and solvates thereof. The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.

Protein kinase C inhibitor

The present invention provides a method for synthesizing indolylmaleimides by reacting an activated maleimide preferably with an optionally substituted organometalic-3-indole in the presence of a transition metal catalyst.

Synthesis of indolymaleimides

This invention provides novel bis-indolylmaleimide macrocycle derivatives of the formula: and solvates thereof. The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.

The present invention provides for the reaction of optionally substituted indole-3-acetamides with optionally substituted methyl indole-3-glyoxyl reagent to prepare potent PKC inhibitors. The reaction is a very efficient and robust macrocyclization methodology.

Synthesis of bisindolylmaleimides

The present invention provides for the reaction of optionally substituted indole-3-acetamides with optionally substituted methyl indole-3-glyoxyl reagent to prepare potent PKC inhibitors.

The present invention provides a method for synthesizing indolylmaleimides by reacting an activated maleimide preferably with an optionally substituted organometallic-3-indole in the presence of a transition metal catalyst.

Synthesis of indolylmaleimides

This invention provides compounds of the formula: ##STR1## The invention further provides the use of this compound to prepare N,N'-bridged bisindolylmaleimides. Furthermore, the invention provides pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.

Growing community of inventors

Zionsville, IN, United States of America

Margaret Mary Faul